Uniunea Europeană - română - EMA (European Medicines Agency)

csl behring gmbh - human alpha1-proteinase inhibitor - genetic diseases, inborn; lung diseases - hemostatice - respreeza este indicat pentru tratamentul de întreținere, pentru a încetini progresia emfizemului la adulți cu deficit de inhibitor alfa1-proteinază sever. genotipurile pizz, piz (null), pi (null, null), pisz). pacienții trebuie să fie sub tratament farmacologic optim și non-farmacologic și să prezinte dovezi de boală pulmonară progresivă (de ex. mai mic volumul expirator fortat pe secunda (fev1) a prezis, afectată capacitatea de mers pe jos sau a crescut numărul de exacerbari) şi evaluate de către un profesionist din domeniul sanitar, cu experienţă în tratamentul de deficit de alfa1-proteinaza.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

human bioplazma manufacturing and trading ltd. - imunoglobulina normala pt. adm. intravasculara - pulb.+solv. pt. sol. perf. - 5% - imunoglobuline imunoglobulina umana normala

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

verve human care laboratories - morfina - soluţie injectabilă - 10 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

verve human care laboratories - ketaminum - soluţie injectabilă - 50 mg/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenți antitrombotici - prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 pentru haemodynamically instabil pe pacienți). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 și 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Uniunea Europeană - română - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenți antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Uniunea Europeană - română - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - agenți antitrombotici - xarelto, administrat concomitent cu acidul acetilsalicilic (aas) singur sau cu asa plus clopidogrel sau ticlopidina, este indicat pentru prevenirea evenimentelor aterotrombotice la pacienții adulți după un sindrom coronarian acut (sca) cu valori crescute biomarkerii cardiaci. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Uniunea Europeană - română - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat.

Uniunea Europeană - română - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat.

Uniunea Europeană - română - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat.